Ralinepag vs Treprostinil (Tyvaso)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Ralinepag
Developed by United Therapeutics under a licence from Arena Pharmaceuticals, Inc.
NCT03626688 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled, event-driven Phase 3 trial with 687 patients in the full analysis set (728 randomized; 41 patients from sites in China excluded), measuring time to first clinical worsening event as the primary endpoint. The peer-reviewed report in The Lancet gives a hazard ratio of 0.45 (95% CI 0.33-0.62; p<0.0001) for ralinepag versus placebo, with more discontinuations for adverse events on ralinepag (19% vs 3%).
Next expected readout: December 2026 · NCT03683186 (registry estimate)
Reported efficacy
Time from randomization to the first adjudicated protocol-defined clinical worsening event (The study duration was event-based. This parameter was assessed from randomization until the conclusion of the study, up to 3 years): Time to first adjudicated clinical worsening event (ADVANCE OUTCOMES): HR 0.45 (95% CI 0.33-0.62) vs placebo, a 55% risk reduction, p<0.0001. (met)
Result source: NCT03626688
Treprostinil (Tyvaso)
Marketed by United Therapeutics
NCT00147199 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 235 participants, with 115 receiving inhaled treprostinil and 120 receiving placebo. The prespecified clinical primary endpoint—change in peak 6-minute walk distance at Week 12—was met, with a between-group estimate of 20.0 meters (95% CI 8.0–32.8; p=0.00044).
Next expected readout: December 2027 · NCT07177703 (registry estimate)
Reported efficacy
Peak 6-minute Walk Distance (12 weeks): Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) (met)
Result source: NCT00147199
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Ralinepag: 5 of 5 rows · Treprostinil (Tyvaso): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ralinepag | Treprostinil (Tyvaso) |
|---|---|---|
| 6MWD - Change absolute change · m No placebo or comparator arm | -120 m @ 221wka,b,c,d NCT02279745 · Phase 2 · registry result, not featured evidence | 20 m @ 12wka,b,c,d NCT01268553 · Phase 4 · registry result, not featured evidence 1 other source trial230 m @ 12wk NCT00705133 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 44.4%e NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result15% NCT02279160 · Phase 2 · registry result, not featured evidence | 11.3%f NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results0% NCT01268553 · Phase 4 · registry result, not featured evidence 11% NCT00741819 · Phase 4 · registry result, not featured evidence 0% NCT00705133 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 15.6%e NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result— NCT02279160 · Phase 2 · registry result, not featured evidence | —f NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results— NCT01268553 · Phase 4 · registry result, not featured evidence 4.1% NCT00741819 · Phase 4 · registry result, not featured evidence — NCT00705133 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 46.7%e NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more result10% NCT02279160 · Phase 2 · registry result, not featured evidence | 7.8%f NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results0% NCT01268553 · Phase 4 · registry result, not featured evidence 13.7% NCT00741819 · Phase 4 · registry result, not featured evidence 0% NCT00705133 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | e headache 64.4% diarrhoea 37.8% pain in jaw 33.3% NCT02279745 · Phase 2 · registry result, not featured evidence show 1 more resultheadache 77.5% (placebo 28.6%) nausea 50% (placebo 23.8%) diarrhoea 47.5% (placebo 14.3%) NCT02279160 · Phase 2 · registry result, not featured evidence | f cough 53.9% (placebo 29.2%) headache 40.9% (placebo 22.5%) nausea 19.1% (placebo 10.8%) NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 2 more resultsgeneral prostacyclin adverse reaction profile 100% NCT00705133 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 12 weeks versus 221 weeks.
- ePopulation comparability has not been reviewed for these studies.
- fPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ralinepag
Treprostinil (Tyvaso)
show 1 more result
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ralinepag's landscape · Treprostinil (Tyvaso)'s landscape